- Bioniche appointed exclusive Australian distribution of four products
BELLEVILLE, ON, March 22, 2012 /CNW/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that it has entered into a
distribution agreement with a U.S.-based veterinary pharmaceutical
company to expand Bioniche's product offerings in Australia.
The supplier is providing Bioniche with exclusive distribution rights
for four registered injectable animal health products in Australia:
RespiramTM - a respiratory stimulant for dogs, cats and horses, used during and
after anaesthesia or for neonatal dogs and cats following dystocia
(difficult labour) or caesarian section
CepetorTM - a sedative and analgesic for dogs and cats
RevertorTM - for the reversal of the clinical effects of medetomidine in dogs and
CepesedanTM - for use as a sedative and analgesic to facilitate minor surgical and
diagnostic procedures in horses
"These products are important additions to our product portfolio in
Australia, where we are already strong in equine products and are
increasing our focus on the companion animal space," said Mr. Andrew
Grant, President of Bioniche Animal Health (global). "We estimate the
Australian market for products of this type to be up to A$11 million
and, given that these products are already registered, we expect to
start to see revenues within a few months."
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
Bioniche Animal Health develops, manufactures and markets veterinary
biopharmaceutical products worldwide. In North America, it has
development, manufacturing and marketing facilities in Belleville,
Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington,
U.S.A. In Australia, business is conducted from two sites: Sydney, New
South Wales, where sales and marketing, customer support and technical
service are located; and Armidale, New South Wales, where research,
development and manufacturing facilities are located.
Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small
and Medium-Sized Employers in Canada for 2011. For more information,
please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097